Nuwellis Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nuwellis Inc's ROI in the second quarter of 2026?
Nuwellis Inc recorded a cumulative net loss of $-11 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -279.01%.

Within the Healthcare sector 767 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 4384, from total ROI ranking in the first quarter of 2026 at 5055.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-22.27 %	-7.48 %	10.19 %	40.93 %	6.89 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	5	3	3	4	5
Return On Investment (TTM)	-279.01 %	-463.82 %	-401.63 %	-310.54 %	-280.86 %
NUWE's Overall Ranking	# 4384	# 5055	# 4445	# 4480	# 4499
Seq. Investment Change TTM	-1.16 %	-5.88 %	-18.16 %	2.08 %	17.65 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-11	-19	-18	-17	-15

NUWE Company Profile >> Back to NUWE Roi Comparisons >> See Annual NUWE Return On Investment

Return On Investment NUWE's Ranking
Within:	No.
Industry	# 175
Sector	# 768
Overall	# 4384

Return On Investment Statistics
High	Average	Low
-52.67 %	-170.37 %	-463.82 %
(Jun 30 2014)		(Mar 31 2026)

News about Nuwellis Inc Return on Investment ROI

Nuwellis Bold Leap: Medicare Reimbursement Surge Amid Struggling ROI Performance

November 4, 2024

In a move destined to reshape its financial outlook, Nuwellis Inc. announced a staggering 397% daily increase in the reimbursement rate for its Aquadex SmartFlow Therapy, effective January 1, 2025, from the Centers for Medicare and Medicaid Services (CMS). This monumental improvement comes on the heels of a more modest, but still impressive, 112.88% increase over the trailing 30 days. This development signals a potentially transformative shift for a company facing significant financial headwinds.Despite these encouraging changes in reimbursement, Nuwellis has been grappling with substantial fiscal challenges. The company recorded a cumulative net loss of $20 million during the twelve months ending in the second quarter of 2024, translating to a negative return on investment (ROI) of -408.65%. Such a figure starkly highlights the struggles of a company still in the throes of establishing its product in a competitive healthcare landscape.

Nuwellis Announces Purchase Agreement with Major Hospital Network for Aquadex Ultrafiltration Therapy

May 9, 2024

MINNEAPOLIS, May 09, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a leading medical technology company specializing in fluid overload treatment, has recently finalized a purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the United States. This collaboration marks a significant milestone for Nuwellis as it expands its reach and impact within the healthcare industry.
Under the new agreement, Nuwellis will provide its innovative Aquadex Ultrafiltration Therapy to a network of 50 hospitals. Aquadex is a proven technology that is transforming the lives of patients suffering from fluid overload. This therapy uses a gentle, adjustable method to remove excess fluid from the body, fostering better patient outcomes and improving quality of life.

Financial Statements
Nuwellis Inc's II. Quarter Investments	$ 5 Millions	NUWE's Balance sheet
Nuwellis Inc's II. Quarter Income	$ -5 Millions	Quarterly NUWE's Income Statement
NUWE's Income by Division		See NUWE's Income by Division

NUWE Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	3	7	7	20	27
Y / Y Investment Growth	-64 %	10.72 %	-66.99 %	-26.28 %	65.03 %
Net Income in Millions	-18	-10	-20	-15	-20
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-666.2 %	-138.03 %	-308.12 %	-72.68 %	-72.22 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NUWE's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NUWE's Competitors
Subscribers only: Roi for Nuwellis Inc's Suppliers
Subscribers only: Return On Investment for NUWE's Customers

Other Ratios
NUWE's Roa	NUWE's Inventory Turnover Ratio	NUWE's Growth Rates	NUWE's Dividend Statistics
	NUWE's Profitability Ratios	NUWE's Asset Turnover Ratio	NUWE's Dividend Growth
NUWE's Roe	NUWE's Valuation Ratios	NUWE's Financial Strength Ratios	NUWE's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-03T12:04:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.